0001415889-24-018079.txt : 20240624
0001415889-24-018079.hdr.sgml : 20240624
20240624202146
ACCESSION NUMBER: 0001415889-24-018079
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: KALA BIO, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 241065957
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
FORMER COMPANY:
FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20091223
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Iwicki Mark T
CENTRAL INDEX KEY: 0001415537
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: 84 WATERFORD DRIVE
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
144
1
primary_doc.xml
144
0001415537
XXXXXXXX
LIVE
0001479419
KALA BIO, INC.
001-38150
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
781-996-5252
Mark T Iwicki
Officer
Director
Common Stock
ETRADE FINANCIAL CORPORATION
3 EDISON DRIVE
ALPHARETTA
GA
30005
14210
69626.59
2816454
06/24/2024
NASDAQ
Common Stock
06/24/2024
Restricted Stock Unit Vesting
Issuer
N
52952
06/24/2024
Equity Compensation
N
Mark T Iwicki
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
Common Stock
05/31/2024
7392
45031.18
Represents the sale of shares of common stock pursuant to a "sell-to-cover" transaction in order to satisfy tax withholding obligations in connection with the vesting of RSUs previously granted to the Reporting Person. This sale was effected pursuant to an automatic sell-to-cover instruction effected pursuant to Rule 10b5-1 adopted by the Reporting Person on November 9, 2020 and does not represent a discretionary sale by the Reporting Person.
06/24/2024
/s/ Mary Reumuth, Attorney-in-Fact